Abraham S, Duncan E
Methods Mol Biol. 2023; 2663:569-588.
PMID: 37204737
DOI: 10.1007/978-1-0716-3175-1_37.
Escobar M, Mancuso M, Hermans C, Leissinger C, Seifert W, Li Y
J Clin Med. 2022; 11(4).
PMID: 35207344
PMC: 8875492.
DOI: 10.3390/jcm11041071.
Depasse F, Binder N, Mueller J, Wissel T, Schwers S, Germer M
J Thromb Haemost. 2021; 19(12):2907-2917.
PMID: 34525255
PMC: 9291770.
DOI: 10.1111/jth.15529.
Rosen S, Tiefenbacher S, Robinson M, Huang M, Srimani J, Mackenzie D
Blood. 2020; 136(22):2524-2534.
PMID: 32915950
PMC: 7714098.
DOI: 10.1182/blood.2020005683.
Nederlof A, Kitchen S, Meijer P, Cnossen M, Ali Pour N, Kershaw G
J Thromb Haemost. 2020; 18(8):1874-1883.
PMID: 32311825
PMC: 7496271.
DOI: 10.1111/jth.14847.
Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer J, Sadeghi-Khomami A, Barnowski C, Wiken M, Willemze A
Int J Lab Hematol. 2020; 42(3):350-358.
PMID: 32202380
PMC: 7318191.
DOI: 10.1111/ijlh.13189.
Activity measurements of dalcinonacog alfa.
Williams S, Gray E
Haemophilia. 2020; 26(2):346-353.
PMID: 32142203
PMC: 7891335.
DOI: 10.1111/hae.13949.
Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
Fukutake K, Kobayashi T, Sommer J, Hirakata T
Int J Lab Hematol. 2019; 42(2):162-169.
PMID: 31820573
PMC: 7078902.
DOI: 10.1111/ijlh.13133.
Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Marlar R, Strandberg K, Shima M, Adcock D
Eur J Haematol. 2019; 104(1):3-14.
PMID: 31606899
PMC: 6916414.
DOI: 10.1111/ejh.13339.
A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
Tiefenbacher S, Clausen W, Hansen M, Lutzhoft R, Ezban M
Haemophilia. 2019; 25(5):893-901.
PMID: 31294905
PMC: 6852407.
DOI: 10.1111/hae.13813.
Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
Chowdary P, Carcao M, Holme P, Jimenez-Yuste V, Lentz S, Moss J
Res Pract Thromb Haemost. 2019; 3(3):542-554.
PMID: 31294338
PMC: 6611478.
DOI: 10.1002/rth2.12220.
Estimation of Nuwiq (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.
Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga J
Haemophilia. 2019; 25(4):708-717.
PMID: 31106957
PMC: 6851970.
DOI: 10.1111/hae.13763.
Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
Leksa N, Aleman M, Goodman A, Rabinovich D, Peters R, Salas J
J Thromb Haemost. 2019; 17(7):1044-1052.
PMID: 30887655
PMC: 6850022.
DOI: 10.1111/jth.14430.
Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C, Negrier C, Kalina U, Seifert W, Friedman K
J Thromb Haemost. 2018; 17(1):138-148.
PMID: 30418692
PMC: 7379984.
DOI: 10.1111/jth.14332.
Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
Sommer J, Buyue Y, Bardan S, Peters R, Jiang H, Kamphaus G
Thromb Haemost. 2014; 112(5):932-40.
PMID: 25144892
PMC: 6374931.
DOI: 10.1160/TH13-11-0971.
